Press Release: Committee for orphan medicines – overview of 2013 and looking ahead

Author (Corporate)
Series Title
Series Details 03.02.14
Publication Date 03/02/2014
Content Type

A total of 11 out of 81 medicines recommended for marketing authorisation by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in 2013 were intended for the treatment of rare diseases. This continues the year-on-year increase in the number of marketing authorisation recommendations for medicines for rare diseases observed over the last few years (with 8 in 2012 and 4 in 2011).
Source Link http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/01/news_detail_002016.jsp&mid=WC0b01ac058004d5c1
Related Links
ESO: Background information: Press Release: EMA recommends 81 medicines for marketing authorisation in 2013 http://www.europeansources.info/record/press-release-ema-recommends-81-medicines-for-marketing-authorisation-in-2013/
EMA: Legal background: orphan designation http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000552.jsp&mid=WC0b01ac058061ecb7
Subject Categories
Countries / Regions